{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:40:01Z","timestamp":1792003201766,"version":"4.4.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>The objective is to assess whether the degree of metabolic uptake of the primary tumor and axillary lymph nodes (ALNs) on baseline [<jats:sup>18<\/jats:sup>F] fluorodeoxyglucose ([<jats:sup>18<\/jats:sup>F]FDG) PET\/CT is associated with the probability to achieve axillary pathologic complete response (pCR) in clinically node-positive (cN+) breast cancer patients treated with neoadjuvant systemic therapy (NST), overall and per clinical subtype. Studies that assessed the maximum standardized uptake value (SUVmax) in the primary tumor and ALNs on baseline [<jats:sup>18<\/jats:sup>F]FDG PET\/CT and reported axillary pCR rates in patients diagnosed with cN+ invasive breast cancer treated with NST, followed by surgery, were searched. Area under the curve (AUC) values were obtained. A total of seven studies (561 patients) were included. The mean baseline SUVmax of the primary tumor ranged from 8.1 (\u00b14.3) to 9.8 (\u00b17.2). Mean baseline axillary SUVmax ranged from 6.0 (\u00b15.6) to 7.3 (\u00b16.2). The axillary pCR rate ranged from 38.0% to 48.1%. Considering the primary tumor, no study reported on the association between baseline SUVmax and the axillary pCR rate. Considering the ALNs, the AUC value for baseline axillary SUVmax to predict axillary pCR ranged from 0.52 [95% confidence interval (CI): 0.39\u20130.65; all subtypes included] to 0.74 (95% CI: 0.53\u20130.95; only human epidermal growth factor receptor 2+ and triple negative). In conclusion, no association between the primary tumor SUVmax on baseline [<jats:sup>18<\/jats:sup>F]FDG PET\/CT and axillary pCR was found. Concerning the axilla, based on limited scientific evidence, the axillary SUVmax on baseline [<jats:sup>18<\/jats:sup>F]FDG PET\/CT may be associated with axillary pCR after NST in cN+ breast cancer patients, however, potential differences between clinical subtypes should be considered.<\/jats:p>","DOI":"10.1097\/mnm.0000000000001964","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:03:00Z","timestamp":1740466980000},"page":"384-391","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A review of the association between baseline [18F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-4375","authenticated-orcid":false,"given":"Melissa","family":"Lenaerts","sequence":"first","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Centre+,"},{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florien J. G.","family":"van Amstel","sequence":"additional","affiliation":[{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University,"},{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix M.","family":"Mottaghy","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands,"},{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen University, Aachen, Germany\u2002and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M. E.","family":"Geurts","sequence":"additional","affiliation":[{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University,"},{"name":"Department of Medical Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne C. G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University,"},{"name":"Department of Medical Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Centre+,"},{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiemo J. A.","family":"van Nijnatten","sequence":"additional","affiliation":[{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University,"},{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"R1-20250403","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-020-05589-3","article-title":"De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.","volume":"180","author":"Simons","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"R2-20250403","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.soc.2014.03.006","article-title":"Neoadjuvant therapy in the treatment of breast cancer.","volume":"23","author":"Teshome","year":"2014","journal-title":"Surg Oncol Clin N Am"},{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis.","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.21873\/anticanres.13031","article-title":"Evaluation of the usefulness of FDG-PET\/CT for nodal staging of breast cancer.","volume":"38","author":"Orsaria","year":"2018","journal-title":"Anticancer Res"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1148\/radiol.2015141638","article-title":"Early metabolic response to neoadjuvant treatment: FDG PET\/CT criteria according to breast cancer subtype.","volume":"277","author":"Groheux","year":"2015","journal-title":"Radiology"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4274\/ejbh.galenos.2023.2023-1-3","article-title":"Role of F-18 FDG PET\/CT in predicting response to neoadjuvant chemotherapy in invasive ductal breast cancer.","volume":"19","author":"Sengoz","year":"2023","journal-title":"Eur J Breast Health"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","article-title":"FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer.","volume":"22","author":"Koolen","year":"2013","journal-title":"Breast"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13550-023-00953-y","article-title":"The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis.","volume":"13","author":"de Mooij","year":"2023","journal-title":"EJNMMI Res"},{"key":"R9-20250403","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R10-20250403","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range.","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"R11-20250403","first-page":"3","article-title":"The prognostic role of baseline (18)F-FDG PET\/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy.","volume":"41","author":"Can","year":"2022","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"R12-20250403","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00259-013-2657-7","article-title":"Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET\/CT in patients with locally advanced breast cancer.","volume":"41","author":"Garcia Vicente","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20250403","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1245\/s10434-013-2902-0","article-title":"Early assessment of axillary response with (1)(8)F-FDG PET\/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.","volume":"20","author":"Koolen","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R14-20250403","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13550-021-00861-z","article-title":"Value of (18)F-FDG PET\/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype.","volume":"11","author":"de Mooij","year":"2021","journal-title":"EJNMMI Res"},{"key":"R15-20250403","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40644-017-0117-5","article-title":"Additional value of (18)F-FDG PET\/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.","volume":"17","author":"van Ramshorst","year":"2017","journal-title":"Cancer Imaging"},{"key":"R16-20250403","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2013.469","article-title":"HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.","volume":"109","author":"Groheux","year":"2013","journal-title":"Br J Cancer"},{"key":"R17-20250403","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4274\/mirt.galenos.2022.44154","article-title":"The value of (18)F-FDG PET\/CT imaging in the evaluation of interim neoadjuvant chemotherapy response in locally advanced breast cancer.","volume":"31","author":"Tatar","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"key":"R18-20250403","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00259-018-3998-z","article-title":"Tumor metabolism assessed by FDG-PET\/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.","volume":"45","author":"Groheux","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20250403","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5152\/eurasianjmed.2018.18036","article-title":"Relationship between 18-FDG-PET\/CT and clinicopathological features and pathological responses in patients with locally advanced breast cancers.","volume":"51","author":"Yildirim","year":"2019","journal-title":"Eurasian J Med"},{"key":"R20-20250403","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s00259-012-2211-z","article-title":"Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.","volume":"39","author":"Koolen","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20250403","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejrad.2018.05.014","article-title":"The prognostic value of SUV(max) measuring on primary lesion and ALN by (18)F-FDG PET or PET\/CT in patients with breast cancer.","volume":"105","author":"Diao","year":"2018","journal-title":"Eur J Radiol"},{"key":"R22-20250403","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/MNM.0000000000000694","article-title":"Correlation of 18F-FDG PET\/CT with pathological features and survival in primary breast cancer.","volume":"38","author":"Simsek","year":"2017","journal-title":"Nucl Med Commun"},{"key":"R23-20250403","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00259-011-1735-y","article-title":"FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.","volume":"38","author":"Rousseau","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20250403","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-023-00953-y","article-title":"The influence of receptor expression and clinical subtypes on baseline [18F] FDG uptake in breast cancer: systematic review and meta-analysis.","volume":"13","author":"de Mooij","year":"2023","journal-title":"EJNMMI research"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:12:53Z","timestamp":1743725573000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000001964","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}